Texas Cancer Biotechnology Company: Actuate Therapeutics (ACTU)

Actate Therapeutics, Inc. (NASDAQ: ACTU), founded in 2015, headquartered in Fort Worth, Texas, USA, with 15 full-time employees, is a clinical Biopharmaceutical Company , focusing on the development of therapies to treat high impact and difficult to treat cancers by inhibiting glycogen synthase kinase 3 (GSK-3).

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/actu.html

Actate Therapeutics (ACTU)

Actuate Therapeutics is a Biotechnology Company , aiming to provide patients with cancer that is difficult to treat with opportunities to prolong life and improve life through a first-class drug. This drug has the potential to slow down, stop or shrink tumors, and has minimal side effects. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/actu.html

Actate Therapeutics is developing the leading drug elraglusib (formerly 9-ING-41), a small molecule (a new GSK-3 inhibitor) that aims to enter cancer cells and block GSK-3 enzyme function. GSK-3 ß is a major regulator of complex biological signal cascade reactions, including those mediated by oncogenes, which lead to the survival, growth, migration and invasion of tumor cells. Elraglusib also becomes a medium of anti-tumor immunity by inhibiting multiple immune checkpoints and regulating the function of immune cells. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/actu.html

Actuate Therapeutics believes that the blocking of GSK-3 signaling will eventually lead to the death of cancer cells and the regulation of anti-tumor immunity. Actate has exclusively licensed a patent portfolio of GSK-3 inhibitors, which were jointly developed at the University of Illinois at Chicago (UIC) and Northwestern University (NU). ELAGLUSIB (9-ING-41) is currently conducting a randomized phase II clinical trial for patients with metastatic pancreatic cancer, which is the most advanced clinical indication of Actuate so far. Based on the data obtained from the Phase I/Phase II clinical trials completed or under way in children and adults with advanced and refractory cancer, ellaglutib provides a broad opportunity for the company to launch and promote multiple drug development projects around this major asset. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/actu.html

About GSK-3 β The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/actu.html

GSK-3 β has been an attractive target in cancer treatment for a long time, but the previously developed candidate drugs for inhibiting GSK-3 β are limited due to their poor drug properties and/or significant adverse reactions to patients, thus limiting their clinical application. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/actu.html

GSK-3 β is an enzyme that can regulate many cross biological pathways related to diseases (especially cancer). GSK-3 β drives tumor progression by promoting cancer cell proliferation, resistance and survival in progressive and metastatic diseases. GSK-3 β seems to be involved in promoting the growth and survival of many different cancer types, making it a key target for developing new first-class therapies such as elraglusib. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/actu.html

Actual Therapeutics product line

Actate Therapeutics (ACTU) Historical Encyclopedia

On January 16, 2015, the company was founded in the name of Apotheca Therapeutics, Inc. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/actu.html

On October 29, 2015, Actuate established a scientific advisory committee. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/actu.html

March 29, 2016, USA food And the Drug Administration (FDA) granted 9-ING-41 orphan drug qualification for the treatment of glioblastoma. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/actu.html

On March 31, 2017, Actuate technology was introduced in the molecular pathway section of Clinical Cancer Research.

On August 18, 2017, FDA granted 9-ING-41 an additional orphan drug qualification for the treatment of neuroblastoma.

On February 15, 2018, FDA accepted the 9-ING-41 IND application of Actuate and approved the clinical study of advanced cancer patients.

On December 17, 2018, Actuate Company treated the first patient in the first/second phase of 9-ING-41 clinical study for patients with refractory cancer.

On July 31, 2020, Actuate announced to launch the Phase II clinical study of pancreatic cancer.

On August 4, 2021, Actuate announced that 9-ING-41 was granted the fast track qualification by FDA for the treatment of pancreatic cancer.

On October 27, 2021, Actuate announced that the phase II study of 9-ING-41 pancreatic cancer had met the main expectations.

On February 7, 2022, Actuate announced the launch of a multicenter randomized trial of ellaglutib combined with FOLFIRONOX as a first-line treatment for advanced pancreatic cancer.

Actate Therapeutics (ACTU) US equity investment

On May 24, 2024, Actate Therapeutics, a phase II biotechnology company developing licensed inhibitor therapy for treatment of refractory cancer, submitted to the SEC on Friday IPO It is proposed to raise up to US $50 million through IPO. Actuate plans to be listed on NASDAQ, with the stock code of ACTU. Titan Partners is the sole bookrunner of the transaction. Pricing terms are not disclosed.

On June 11, 2024, Actual Therapeutics announced that it planned to issue 5.6 million shares at a price range of 8 to 10 dollars per share, raising 50 million dollars. According to the median value of the proposed range, the fully diluted market value of Actuate Therapeutics will reach 207 million dollars.